

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-27 (Canceled).

28 (Previously Presented): A stabilized solid composition comprising a 4-amino-3-substituted butanoic acid derivative and propylene glycol, wherein the 4-amino-3-substituted butanoic acid derivative is gabapentin or pregabalin.

Claims 29-34 (Canceled).

35 (Previously Presented): The stabilized solid composition of claim 28, wherein the amount of the propylene glycol is 0.01-25 % by weight relative to the 4-amino-3-substituted butanoic acid derivative.

36 (Previously Presented): The stabilized solid composition of claim 28, further comprising an auxiliary agent.

37 (Previously Presented): The stabilized solid composition of claim 36, wherein the total amount of the propylene glycol is 0.01-25 % by weight relative to the 4-amino-3-substituted butanoic acid derivative and the auxiliary agent.

Claims 38-39 (Canceled).

40 (Currently Amended): The stabilized solid composition of claim 28, wherein the stabilized solid composition is a ~~pharmaceutical preparation in the form of~~ tablets, granules or capsules.

41 (Previously Presented): A process for stabilizing a solid composition containing a 4-amino-3-substituted butanoic acid derivative, the process comprising combining the 4-amino-3-substituted butanoic acid derivative with propylene glycol, wherein the 4-amino-3-substituted butanoic acid derivative is gabapentin or pregabalin.

42 (Canceled).

Claim 43 (Previously Presented): The stabilized solid composition of claim 28, wherein after storage of the composition in a sealed container at 60°C for 2 weeks the content of the corresponding lactam that is formed in the composition is less than 0.20% by weight relative to the initial amount of the 4-amino-3-substituted-butanoic acid derivative in the composition.